Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

High-affinity CD16-expressing natural killer cell therapy - ImmunityBio

Next Previous
Drug Profile

High-affinity CD16-expressing natural killer cell therapy - ImmunityBio

Alternative Names: CD-16 NK-92 cells; haNK; High affinity natural killer cells - ImmunityBio; NK-92 [CD16.158V, ER IL-2]

Latest Information Update: 28 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NantKwest
  • Developer ImmunityBio
  • Class Antineoplastics; Cell adhesion molecules; Cell therapies; Gene therapies; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Merkel cell carcinoma
  • Phase I/II Colorectal cancer; Liver cancer; Pancreatic cancer; Squamous cell cancer; Triple negative breast cancer
  • No development reported Head and neck cancer; HER2 positive breast cancer; Solid tumours

Most Recent Events

  • 28 Dec 2021 No recent reports of development identified for clinical-Phase-Unknown development in Head-and-neck-cancer(Refractory metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 08 Oct 2021 ImmunityBio terminates a phase II QUILT-3.063 trial in Merkel cell carcinoma (Combination therapy, Second line therapy or greater) in USA (NCT03853317)
  • 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top